Chantal Csajka

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


165 publications

Sous presse | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999 | 1998 | 1997 | 1996 |
 
Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review
Cardoso E., Guidi M., Blanchet B., Schneider M.P., Decosterd L.A., Buclin T., Csajka C., Widmer N. Therapeutic drug monitoring. Peer-reviewed.
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K., Guidi M., André P., Giannoni E., Basterrechea S., Zhao W., Fuchs A., Pfister M., Buclin T., Csajka C. Pharmacological research p. 104278. Peer-reviewed.
 
Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.
Dietrich L.G., Barceló C., Thorball C.W., Ryom L., Burkhalter F., Hasse B., Furrer H., Weisser M., Steffen A., Bernasconi E. et al. Clinical infectious diseases. Peer-reviewed.
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update.
Fischer Fumeaux C.J., Morisod Harari M., Weisskopf E., Eap C.B., Epiney M., Vial Y., Csajka C., Bickle Graz M., Panchaud A., 2019/10. Expert opinion on drug safety, 18 (10) pp. 949-963. Peer-reviewed.
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2690-2697. Peer-reviewed.
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. et al., 2019/08/01. The Journal of antimicrobial chemotherapy, 74 (8) pp. 2468-2470. Peer-reviewed.
 
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Glatard A., Guidi M., Dobrinas M., Cornuz J., Csajka C., Eap C.B., 2019/07. European journal of clinical pharmacology, 75 (7) pp. 939-949. Peer-reviewed.
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Guidi M., Mercier T., Aouri M., Decosterd L.A., Csajka C., Ogutu B., Carn G., Kiechel J.R., 2019/04/18. Malaria journal, 18 (1) p. 139. Peer-reviewed.
 
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Jermini M., Dubois J., Rodondi P.Y., Zaman K., Buclin T., Csajka C., Orcurto A., E Rothuizen L., 2019/03/25. Scientific reports, 9 (1) p. 5078. Peer-reviewed.
 
Reply to L. Pala et al.
Wagner A.D., Özdemir B., Csajka C., 2019/02/10. Journal of clinical oncology, 37 (5) pp. 439-440. Peer-reviewed.
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Sottas O., Guidi M., Thieffry B., Schneider M., Décosterd L., Mueller I., Genton B., Csajka C., Senn N., 2019. PloS one, 14 (2) pp. e0210789. Peer-reviewed.
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
 
Quelle alternative aux benzodiazépines, Z-pills et autres hypnotiques pour les personnes âgées ?: Mélatonine, valériane ou clométhiazole [Which alternative to benzodiazepines, Z-pills and other hypnotics for aged people ? Melatonin, valerian, or clomethiazole]
Dumur J., Csajka C., Pavec O., Messaoudi S., Cretignier T., Gaspar F., Lang P.O., 2018/11/07. Revue medicale suisse, 14 (626) pp. 2018-2023. Peer-reviewed.
 
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.
Özdemir B.C., Csajka C., Dotto G.P., Wagner A.D., 2018/09/10. Journal of clinical oncology, 36 (26) pp. 2680-2683. Peer-reviewed.
 
Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.
Fournier A., Goutelle S., Que Y.A., Eggimann P., Pantet O., Sadeghipour F., Voirol P., Csajka C., 2018/09. Antimicrobial agents and chemotherapy, 62 (9) pp. e00505-18. Peer-reviewed.
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
 
Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations.
van Donge T., Pfister M., Bielicki J., Csajka C., Rodieux F., van den Anker J., Fuchs A., 2018/04. Antimicrobial agents and chemotherapy, 62 (4) pp. e02004-17 . Peer-reviewed.
 
Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.
Panchaud A., Rousson V., Vial T., Bernard N., Baud D., Amar E., De Santis M., Pistelli A., Dautriche A., Beau-Salinas F. et al., 2018/03. British journal of clinical pharmacology, 84 (3) pp. 568-578. Peer-reviewed.
 
Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L., Joerger M., Wicha S.G., Ter Heine R., Csajka C., Parra-Guillen Z.P., Kloft C., 2018/02. Clinical pharmacokinetics, 57 (2) pp. 229-242. Peer-reviewed.
 
Détection des prescriptions inappropriées, les critères STOPP/START [Detection of inappropriate prescribing, STOPP/START criteria]
Lang Pierre Olivier, Bourgue Chloé, Csajka Chantal, 2018/01. Actualités Pharmaceutiques, 57 (572) pp. 26-32. Peer-reviewed.
 
Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
Cardoso E., Csajka C., Schneider M.P., Widmer N., 2018/01. Clinical pharmacokinetics, 57 (1) pp. 1-6. Peer-reviewed.
 
Détecter et évaluer l’impact desmédicaments anticholinergiques [Detecting and assessing the impactof anticholinergic medications]
Csajka C., Brémond C., Lang P.O., 2017/11/08. Revue medicale suisse, 13 (582) pp. 1931-1937. Peer-reviewed.
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Glatard A., Dobrinas M., Gholamrezaee M., Lubomirov R., Cornuz J., Csajka C., Eap C.B., 2017/10. Experimental and clinical psychopharmacology, 25 (5) pp. 353-362. Peer-reviewed.
 
Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2017/07/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1057 pp. 101-109. Peer-reviewed.
 
Pharmacometrics-based decision tools facilitate mHealth implementation.
Nekka F., Csajka C., Wilbaux M., Sanduja S., Li J., Pfister M., 2017/04. Expert review of clinical pharmacology, 10 (1) pp. 39-46. Peer-reviewed.
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
 
Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2016/11/30. Journal of pharmaceutical and biomedical analysis, 131 pp. 233-245. Peer-reviewed.
 
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Fuchs A., Rotzinger A., Cavassini M., Bugnon O., Buclin T., Schneider M.P., Csajka C., 2016/08. Therapeutic drug monitoring, 38 (4) pp. 506-515. Peer-reviewed.
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
 
Outbreak in meldonium positive laboratory tests: are we missing something?
Panchaud A., Csajka C., 2016/04. British journal of sports medicine, 50 (22) pp. 1422-1423. Peer-reviewed.
 
Bon usage des antidépresseurs ISRS durant la grossesse--le défi de l'évaluation de la balance bénéfice-risque [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].
Weisskopf E., Fumeaux C.J., Bickle Graz M., Harari M.M., Epiney M., Tolsa C.B., Rouiller S., Tolsa J.F., Eap C.B., Vial Y. et al., 2016. Revue Médicale Suisse, 12 (510) pp. 561-566. Peer-reviewed.
 
Cas clinique n°5 - fibrillation auriculaire.
Guignard B., Beney Johnny, Panchaud Alice, Csajka Chantal, Meyer Philippe, 2016. pharmaJournal 07 pp. 5-9.
 
Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.
Wilbaux M., Fuchs A., Samardzic J., Rodieux F., Csajka C., Allegaert K., van den Anker J.N., Pfister M., 2016. Journal of Clinical Pharmacology, 56 (8) pp. 909-935. Peer-reviewed.
 
Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients.
Panchaud A., Di Paolo E.R., Koutsokera A., Winterfeld U., Weisskopf E., Baud D., Sauty A., Csajka C., 2016. Respiration; international review of thoracic diseases, 91 (4) pp. 333-348. Peer-reviewed.
Utility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical Setting.
Corbel A., Baud D., Chaouch A., Beney J., Csajka C., Panchaud A., 2016. Plos One, 11 (3) pp. e0151205. Peer-reviewed.
 
Suivi thérapeutique pharmacologique des inhibiteurs de protéines kinases
Buclin Thierry, Csajka Chantal, Guiducci Carlotta, Decosterd Laurent A, 2015/09. Innovations & Thérapeutiques en Oncologie, 1 (1) pp. 12-23.
 
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd L.A., Widmer N., Zaman K., Cardoso E., Buclin T., Csajka C., 2015/09. Biomarkers In Medicine, 9 (9) pp. 887-893. Peer-reviewed.
 
Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.
Guidi M., Foletti G., McLaren P., Cavassini M., Rauch A., Tarr P.E., Lamy O., Panchaud A., Telenti A., Csajka C. et al., 2015/07. Antiviral Therapy, 20 (3) pp. 261-269. Peer-reviewed.
 
Cas clinique n°4 - prescription inappropriée chez le patient âgé: entre trop et trop peu de médicaments.
Csajka Chantal, Panchaud Alice, Guignard Bertrand, Beney Johnny, Spinewine Anne, 2015. pharmaJournal 7 pp. 5-7.
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., Eap C.B., 2015. Clinical Pharmacokinetics, 54 (12) pp. 1259-1272. Peer-reviewed.
 
Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry.
Rochat B., Dahmane E., Zaman K., Csajka C., 2015. Therapeutic Drug Monitoring, 37 (2) pp. 141-146.
 
Médicaments, grossesse et lactation.
Delaloye J.F., Panchaud A., Weisskopf E., Winterfeld U., Rothuizen L., Vial Y., Csajka C., Buclin T., Hohlfeld P., 2015/01., 4e éd. 252 p, Médecine et Hygiène.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.
Weisskopf E., Fischer C.J., Bickle Graz M., Morisod Harari M., Tolsa J.F., Claris O., Vial Y., Eap C.B., Csajka C., Panchaud A., 2015. Expert Opinion On Drug Safety, 14 (3) pp. 413-427. Peer-reviewed.
 
Cas clinique n° 3 : médicaments et rein
Beney J., Panchaud A., Guignard B., Csajka C., 2014/10. PharmaJournal 21 pp. 5-7.
 
Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
Mosha D., Guidi M., Mwingira F., Abdulla S., Mercier T., Decosterd L.A., Csajka C., Genton B., 2014/08. Antimicrobial Agents and Chemotherapy, 58 (8) pp. 4583-4592. Peer-reviewed.
 
Cas clinique n°2: épilepsie et grossesse.
Panchaud A., Guignard B., Beney J., Baud D., Csajka C., Ferreira E., 2014/06. pharmaJournal, 12 (6) pp. 5-7.
 
Cas clinique n°1 : Insuffisance cardiaque
Guignard B, Beney J, Panchaud A, Csajka C, De Denus S, 2014/03. PharmaJournal, 7 (3) pp. 5-8.
 
Caractérisation du profil pharmacocinétique de la vancomycine chez des patients hospitalisés en médecine générale et chirurgie
Ribeiro J., Cerruti J., Widmer N., Livio F., Buclin T., Csajka C., Guidi M., 2014. dans 2e Congrès Suisse des Pharmaciens.
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L., Baerlocher G.M., Duchosal M.A. et al., 2014. Cancer Chemotherapy and Pharmacology, 74 (6) pp. 1307-1319. Peer-reviewed.
Dosing regimen of gentamicin in neonates: evaluation of current guidelines based on a large population pharmacokinetic analysis
Fuchs A., Guidi M., Giannoni E., Werner D., Widmer N., Buclin T., Csajka C., 2014. dans ESCIM 2014, European and Swiss Congress of Internal Medicin.
 
EzeCHiel: a story of individualized medicine validation - case of gentamicin dosing regimen optimisation in newborns
Fuchs A., Thoma Y., Sutter Y., Stadelmann J., Csajka C., Guidi M., Buclin T., Widmer N., 2014. dans Nano-Tera Annual Plenary Meeting 2014: Virtual Edition.
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
 
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V., Bouchet S., Widmer N., Schuld P., Decosterd L.A., Buclin T., Mahon F.X., Csajka C., Molimard M., 2014. Leukemia Research, 38 (7) pp. 764-772. Peer-reviewed.
 
Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique [Pharmacokinetic Alterations in Pregnancy and Use of Therapeutic Drug Monitoring].
Panchaud A., Weisskopf E., Winterfeld U., Baud D., Guidi M., Eap C.B., Csajka C., Widmer N., 2014. Therapie, 69 (3) pp. 223-234. Peer-reviewed.
 
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Stancu I., Alnawaqil A.M., Bula C. et al., 2014. British Journal of Clinical Pharmacology, 78 (1) pp. 135-144. Peer-reviewed.
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
 
Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.
Fuchs A., Guidi M., Giannoni E., Werner D., Buclin T., Widmer N., Csajka C., 2014. British Journal of Clinical Pharmacology, 78 (5) pp. 1090-1101. Peer-reviewed.
 
Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.
Dahmane E., Boccard J., Csajka C., Rudaz S., Décosterd L., Genin E., Duretz B., Bromirski M., Zaman K., Testa B. et al., 2014. Analytical and Bioanalytical Chemistry, 406 (11) pp. 2627-2640. Peer-reviewed.
 
Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey.
Csajka C., Jaquet A., Winterfeld U., Meyer Y., Einarson A., Panchaud A., 2014. Swiss Medical Weekly, 144 pp. w13936.
Tobramycin exposure from active calcium sulfate bone graft substitute.
Livio F., Wahl P., Csajka C., Gautier E., Buclin T., 2014. Bmc Pharmacology and Toxicology, 15 (1) p. 12. Peer-reviewed.
 
Antidépresseurs, grossesse et allaitement : une étude multicentrique
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J-F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
 
Benchmarking therapeutic drug monitoring software: A review of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2013. Clinical Pharmacokinetics, 52 (1) pp. 9-22. Peer-reviewed.
 
Certificat de formation continue en Pharmacie clinique: une nouvelle opportunité de formation.
Panchaud A., Csajka C., 2013. PharmaJournal, 12 (6) pp. 17-18.
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from the randomized controlled I-COME Trial
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Benz R., Gregor M., Leoncini-Franscini L., Baerlocher G., Duchosal M. et al., 2013. pp. e6 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
 
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M., Crettol S., Oneda B., Lahyani R., Rotger M., Choong E., Lubomirov R., Csajka C., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (2) pp. 84-93. Peer-reviewed.
 
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.
Staehli Hodel E.M., Csajka C., Ariey F., Guidi M., Kabanywanyi A.M., Duong S., Decosterd L.A., Olliaro P., Beck H.P., Genton B., 2013. Antimicrobial Agents and Chemotherapy, 57 (2) pp. 950-958.
 
Etude multicentrique: antidépresseurs, grossesse et allaitement.
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J.F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
 
EzeCHiel validation: Comparison of gentamicin drug concentration predictions to a reference method (NONMEM)
Fuchs A., Thoma Y., Csajka C., Buclin T., Widmer N., 2013. dans Nano-Tera Annual Plenary Meeting.
Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model.
Schenkel F., Csajka C., Baglivo E., Kondo-Oestreicher M., Dayer P., Gex-Fabry M., Daali Y., 2013. Journal of Antimicrobial Chemotherapy, 68 (7) pp. 1635-1641. Peer-reviewed.
 
Medikamente, Schwangerschaft und Stillzeit: nicht alle Informationsquellen sind verlässlich
Panchaud A., Berger J., Csajka C., Bugnon O., 2013. PharmaJournal, 151 (1) pp. 16-17.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Médicaments tocolytiques: utilisation en cas de menace d'accouchement prématuré.
Weisskopf E., Lepigeon K., Baud D., Csajka C., Panchaud A., 2013. PharmaJournal, 19 (9) pp. 5-7.
 
Médicaments, grossesse et allaitement: toutes les sources d'information ne sont pas fiables!
Panchaud A., Berger J., Csajka C., Bugnon O., 2013. PharmaJournal, 151 (1) pp. 15-16.
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
Population pharmacokinetic study of gentamicin: A retrospective analysis in a large cohort of neonate patients
Fuchs A., Guidi M., Giannoni E., Buclin T., Widmer N., Csajka C., 2013. pp. Abstract 2906 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Alnawaqil A.M., Maurer S., Zumbach S. et al., 2013. Clinical Pharmacokinetics, 52 (3) pp. 211-223. Peer-reviewed.
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
 
Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations.
Noetzli M., Guidi M., Ebbing K., Eyer S., Zumbach S., Giannakopoulos P., von Gunten A., Csajka C., Eap C.B., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 270-275. Peer-reviewed.
Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients
Gotta V., Buclin T., Widmer N., Csajka C., 2013. pp. Abstract 2904 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes
Gotta V., Buclin T., Csajka C., Widmer N., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 150-167. Peer-reviewed.
 
Antimicrobial Agents
Csajka C., Marchetti O., Manuel O., Decosterd L., Telenti A., 2012. pp. 379-402 dans Anzenbacher P., Zanger U.M. (eds.) Metabolism of Drugs and Other Xenobiotics chap. 14, Wiley-VCH Verlag.
 
Bedeutet eine radiologische Untersuchung immer eine Gefahr für das ungeborene Kind?
Panchaud A., Verdun F.R., Csajka C., 2012. PharmaJournal, 150 (17) pp. 8-11.
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. pp. 113S-114S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. p. 2351 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. dans Nano-Tera Annual Plenary Meeting.
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A., Csajka C., Buclin T., Bolay S., Bille J., Calandra T., Marchetti O., 2012. Clinical Infectious Diseases, 55 (3) pp. 381-390.
 
Cytogenetic response to imatinib in chronic myeloid leukaemia patients: concentration dependency and associated influences under field-conditions
Gotta V., Bouchet S., Widmer N., Csajka C., Buclin T., Mahon F.-X., Molimard M., 2012. pp. 107S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.
Glass T.R., Rotger M., Telenti A., Decosterd L., Csajka C., Bucher H.C., Günthard H.F., Rickenbach M., Nicca D., Hirschel B. et al., 2012/01. Plos One, 7 (1) pp. e29186. Peer-reviewed.
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
 
Pharmacie clinique en Suisse romande
Guignard B, Csajka Chantal, Beney J, Bugnon Olivier, Bonnabry Pascal, 2012. pp. 1277-1290 dans Calop J, Limat S, Fernandez C, Aulagner G (eds.) Pharmacie clinique et thérapeutique chap. 65, Elsevier Masson.
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
 
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.
Siccardi M., Almond L., Schipani A., Csajka C., Marzolini C., Wyen C., Brockmeyer N.H., Boffito M., Owen A., Back D., 2012. Clinical Pharmacology and Therapeutics, 92 (4) pp. 494-502.
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
 
Population pharmacokinetics in chronic myeloid leukaemia patients: observations under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.-X., Molimard M., Buclin T., Csajka C., 2012. pp. 111S-112S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
Arab-Alameddine M., Buclin T., Guidi M., Widmer N., Decosterd L.A., Csajka C., 2012. pp. Abstr 2441 dans 21st Population Approach Group in Europe (PAGE) meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study.
Panchaud A., Csajka C., Merlob P., Schaefer C., Berlin M., De Santis M., Vial T., Ieri A., Malm H., Eleftheriou G. et al., 2012. Journal of Clinical Pharmacology, 52 (12) pp. 1844-1851. Peer-reviewed.
 
Prevalence, incidence and indications of hypno-sedative treatments in hospitalized patients aged 75 and older
Von Rohr T.R., Rochat S., Monod S., Buela C., Buclin T., Renard D., Csajka C., 2012. p. 228 dans 40th International Symposium on Clinical Pharmacy (ESCP), Clinical Pharmacy: Connecting Care and Outcomes, International Journal of Clinical Pharmacy.
Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.X., Molimard M., Buclin T., Csajka C., 2012. p. 2504 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd L.A., Dahmane E., Neeman M., Buclin T., Csajka C., Haouala A., Widmer N., 2012. pp. 197-250 dans Xu Q.A, Madden T.L. (eds.) LC-MS in drug bioanalysis chap. 9, Springer.
 
Un examen radiologique est-il toujours à risque pour l'enfant à naître?
Panchaud A., Verdun F. R., Csajka C., 2012. PharmaJournal, 150 (17) pp. 5-8.
 
Vancomycin exposure from active calcium sulfate bone filler
Livio F., Guidi M., Wahl P., Gautier E., Prod'Hom G., Buclin T., Csajka T., 2012. pp. 112S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
 
Evaluation of risk perception related to drug use during pregnancy: a swiss survey
Jaquet A., Winterfeld U, Meyer Y., Buclin T., Csajka C., Panchaud A., 2011/02. p. 260 dans Reproductive Toxicology. Peer-reviewed.
 
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C., 2011. Expert Opinion On Drug Metabolism and Toxicology, 7 (5) pp. 609-622.
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy.
Buclin T., Telenti A., Perera R., Csajka C., Furrer H., Aronson J.K., Glasziou P.P., 2011. Plos One, 6 (4) pp. e18578.
 
Evaluation of risk perception related to drug use during pregnancy: a Swiss survey
Jaquet A., Winterfeld U., Meyer Y., Buclin T., Csajka C., Panchaud A., 2011. pp. 422-423 dans 39th ESCP European Symposium on Clinical Pharmacy and 13th SFPC Congress: Clinical Pharmacy at the Front Line of Innovations, International Journal of Clinical Pharmacy. Peer-reviewed.
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
 
Prediction of Infant Drug Exposure Through Breastfeeding: Population PK Modeling and Simulation of Fluoxetine Exposure.
Panchaud A., Garcia-Bournissen F., Csajka C., Kristensen J.H., Taddio A., Ilett K.F., Begg E.J., Ito S., 2011. Clinical Pharmacology and Therapeutics, 89 (6) pp. 830-836. Peer-reviewed.
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
 
Evaluation of the impact of a therapeutic drug monitoring program in a Swiss University Hospital
Fernandez S., Widmer N., Buclin T., Biollaz J., Csajka C., 2010. pp. 283-284 dans ESCP-GSASA, 38th Symposium on Clinical Pharmacy, 30 years of clinical pharmacy : a bright future ahead, Pharmacy World and Science. Peer-reviewed.
 
Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 90S dans 78. Jahresversammlung der Schweizerischen Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
 
Population PK-guided simulation study in children exposed to drugs in human milk
Ito S., Garcia-Bournissen F., Panchaud A., Csajka C., Kristensen J., Taddio A., Ilett K., Begg E., Tomlinson G., 2010. p. 40 dans 16th World Congress of Basic and Clinical Pharmacology, Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
Suivi thérapeutique de l'imatinib
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. Forum Medical Suisse, 10 (23) pp. 403-406. Peer-reviewed.
 
Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 28S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
 
Exposition du nourrisson aux médicaments à travers le lait maternel : évaluation du degré d'exposition
Panchaud Alice, Csajka Chantal, 2009. Pharmajournal, 147 (9) p. 15.
 
Formation et recherche en pharmacie hospitalière et communautaire – état des lieux et perspectives en Suisse romande
Pannatier André, Bugnon Olivier, Csajka Chantal, Bonnabry Pascal, 2009. Pharmactuel, 42 (Suppl. 1) pp. 53-61. Peer-reviewed.
 
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C. et al., 2009. Pharmacogenetics and Genomics, 19 (4) pp. 300-309. Peer-reviewed.
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
 
Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine
Garcia-Bournissen F., Panchaud A., Csajka C., Kristensen J.H.., Taddio A, Ilett K.F., Begg E.J., Ito S., 2009. pp. S1 dans 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Clinical Pharmacology and Therapeutics. Peer-reviewed.
 
Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
Lamoth F., Buclin T., Csajka C., Pascual A., Calandra T., Marchetti O., 2009. Antimicrobial Agents and Chemotherapy, 53 (2) pp. 785-787. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008/07/16. Revue medicale suisse, 4 (165) pp. 1644-1648. Peer-reviewed.
 
Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function
Csajka C., Cavassini M., Rotger M., Decosterd L. A., Furrer H., Calmy A., Fayet A., Arab-Alameddine M., Widmer N., di Iulio J. et al., 2008. Pharmacotherapy, 28 (9) pp. 215e-216e. Peer-reviewed.
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
 
ADME pathway approach for pharmacogenetic studies of anti-HIV therapy
Lubomirov R., Csajka C., Telenti A., 2007/06. Pharmacogenomics, 8 (6) pp. 623-633.
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationships between imatinib plasma levels and efficacy
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. pp. 80S dans 75. Jahresversammlung der Schweizerisches Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Colombo S., Buclin T., Cavassini M., Decosterd L. A., Telenti A., Biollaz J., Csajka C., 2006/11. Antimicrobial Agents and Chemotherapy, 50 (11) pp. 3801-8.
 
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
Rotger M., Csajka C., Telenti A., 2006/09. Current HIV/AIDS reports, 3 (3) pp. 118-25.
 
Pharmacokinetic-pharmacodynamic modelling: history and perspectives
Csajka C., Verotta D., 2006/06. Journal of Pharmacokinetics and Pharmacodynamics, 33 (3) pp. 227-79.
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption
Csajka C., Drover D., Verotta D., 2005/08. Pharmaceutical Research, 22 (8) pp. 1227-35.
 
Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects
Csajka C., Imbimbo B. P., Piccinno A., Dostert P., Verotta D., 2005/05. Journal of Pharmacology and Experimental Therapeutics, 313 (2) pp. 647-57.
 
Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects
Csajka C., Haller C. A., Benowitz N. L., Verotta D., 2005/03. British Journal of Clinical Pharmacology, 59 (3) pp. 335-45.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 116-117 dans 7th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 63S dans 73e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
Csajka C., Marzolini C., Fattinger K., Decosterd L. A., Telenti A., Biollaz J., Buclin T., 2004/09. Antimicrobial Agents and Chemotherapy, 48 (9) pp. 3226-32.
 
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L. A., Stupp R., 2004/06. Clinical Cancer Research, 10 (11) pp. 3728-36.
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
 
Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.
Csajka C., Buclin T., Fattinger K., Brunner H.R., Biollaz J., 2002. Clinical pharmacokinetics, 41 (2) pp. 137-52. Peer-reviewed.
Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients.
Csajka C., Décosterd L.A., Buclin T., Pagani J.L., Fattinger K., Bille J., Biollaz J., 2001/12. European journal of clinical pharmacology, 57 (10) pp. 723-727. Peer-reviewed.
 
Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges
Buclin T., Buchwalder-Csajka C., Brunner H. R., Biollaz J., 1999/10. British Journal of Clinical Pharmacology, 48 (4) pp. 586-93.
 
Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system
Buchwalder-Csajka C., Buclin T., Brunner H. R., Biollaz J., 1999/10. British Journal of Clinical Pharmacology, 48 (4) pp. 594-604.
 
Grossesse et vaccinations
Csajka C., Rousso P., Gysling E., Biollaz J., 1999. Médecine et Hygiène, 57 (2251) pp. 809-811.
 
Impfungen in der Schwangerschaft
Csajka C., Biollaz J., Gysling E., 1998. Pharma-Kritik, 20 (14) pp. 53-56.
 
Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C., Buclin T., Brunner H.R., Biollaz J., 1997. Clinical pharmacokinetics, 32 (1) pp. 1-29. Peer-reviewed.
 
[Reflexions before the introduction of a drug prescription survey at hospitals]
Goubier-Vial C., Csajka C., Ferry S., Rochefort F., Boissel J. P., 1996/02. Thérapie, 51 (1) pp. 57-66.
 
Docteur, puis-je boire de l'alcool avec mes antibiotiques ?
Buchwalder P., Csajka C., Duquenne C., Buclin T., 1996. Médecine et Hygiène, 54 (2114) pp. 829-834.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University